PFSA

Business Context and Reporting Period

Company: Profusa, Inc. (PFSA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Profusa is a clinical-stage digital health company developing biointegrated sensors, specifically the Lumee Oxygen Platform (CE marked in Europe) and the Lumee Glucose Platform (in clinical trials).
Key Event: On July 11, 2025, the Company consummated a Business Combination with NorthView Acquisition Corporation, accounted for as a reverse recapitalization. The Company is now a publicly traded entity on Nasdaq.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Surge: General and Administrative (G&A) expenses increased by 2,636% ($20.2 million) for the three months ended September 30, 2025, compared to the prior year period. This was primarily driven by $15.1 million in transaction costs related to the Business Combination.
• Debt Restructuring: Significant convertible notes and senior notes were converted into common stock upon the closing of the Business Combination on July 11, 2025, reducing interest expense by 84% in the quarter compared to the prior year.
• Capital Structure: The Company completed a reverse recapitalization, converting all preferred stock to common stock. The Company also issued a $10 million PIPE Convertible Note (Tranche 1) and established a $100 million Equity Line of Credit (ELOC).
• Bitcoin Strategy: The Company adopted a Bitcoin treasury strategy, purchasing $1.0 million in Bitcoin during the quarter. Subsequent to the period end, an additional $1.0 million was purchased.

Outlook, Risks, and Contingencies

• Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern within one year due to recurring losses, a working capital deficit of $19.3 million, and the need for additional financing to fund operations and commercialization.
• Nasdaq Compliance: The Company received deficiency notices from Nasdaq regarding failure to maintain the minimum Market Value of Listed Securities ($50 million) and minimum bid price ($1.00). The Company has 180 days (until March 10, 2026) to regain compliance or face delisting.
• Liquidity Strategy: The Company relies on the ELOC and remaining tranches of the PIPE agreement for liquidity. As of September 30, 2025, $3.5 million had been drawn from the ELOC. Subsequent to the period, additional ELOC draws and debt conversions occurred.
• Internal Controls: The Company identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and the valuation of complex financial instruments.
• Bitcoin Risk: The Company faces significant volatility risks associated with its Bitcoin holdings, which are measured at fair value with changes recognized in net income.

Investor Verification Checklist

• Compliance Status: Verify the Company's progress in meeting Nasdaq listing requirements (MVLS and bid price) to avoid delisting.
• Cash Runway: Assess the sufficiency of the $3.0 million cash balance against the $19.3 million working capital deficit and ongoing burn rate.
• Debt Obligations: Review the terms of the $14.4 million related party loan payable and the $2.2 million Tasly Convertible Debt, noting their fair value accounting treatment and potential conversion risks.
• Transaction Costs: Confirm the one-time nature of the $15.1 million transaction costs included in G&A expenses to understand normalized operating costs.
• Bitcoin Volatility: Monitor the impact of Bitcoin price fluctuations on the Company's reported earnings and balance sheet under ASU 2023-08.